RxSS Webinar - Humira and the 2023 Biosimilar Boom

As prescription drug costs continue to rise, payers are looking for ways to mitigate costs and implement strategies to avoid unnecessary expenditures. Will biosimilars be an answer? With a wave of Humira biosimilars hitting the market this year, ending exclusivity for the most profitable biologic drug in the world, what impact will this have on employers, health plans and their members?

This webinar will demonstrate potential savings and share poll results from benefit leaders on how they are adjusting their biosimilar strategy in 2023. It will also provide insights into the:

– Snapshot of the biosimilar market, including potential future state
– Potential impact of rebates on your biosimilar strategy and copay program design
– Patient education and considerations for medication switches
– Questions and scenarios to discuss with your PBM or consultant

Q&A will follow the presentation.

Reserve Your Spot